A total of 1257 patients were screened for participation in the trial and 1090 were enrolled in the placebo run-in phase of the study. Of these, 588 patients entered the treatment phase of the study and were randomized to olmesartan (n=147), losartan (n=150), valsartan (n=145), or irbesartan (n=146).